Related Experiment Video

Updated: Jun 27, 2025

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
09:02

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

13.6K

HMGN1 loss sensitizes lung cancer cells to chemotherapy

Xianli Wu1,2, Geqi Cai3,2, Jing Feng4,5

  • 1Department of Pathology and Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, Anhui, China.

Scientific Reports
|May 6, 2024
PubMed

Insights

High mobility group nucleosome binding (HMGN) proteins are dysregulated in lung adenocarcinoma (LUAD). HMGN1 shows potential as a prognostic biomarker and chemotherapy target due to its role in DNA repair.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • High mobility group nucleosome binding (HMGN) proteins are crucial for nucleosome binding and cellular functions.
  • HMGNs play significant roles in the pathogenesis of various cancers.
  • The specific involvement of HMGN family proteins in lung adenocarcinoma (LUAD) remains underexplored.

Purpose of the Study:

  • To investigate the dysregulation and clinical significance of HMGN family proteins in LUAD.
  • To evaluate HMGN1 as a potential diagnostic marker and prognostic biomarker for LUAD.
  • To elucidate the functional role of HMGN1 in LUAD, particularly in DNA repair pathways and chemosensitivity.

Main Methods:

  • Integrative analysis of multi-omics data from LUAD patient cohorts.
  • Clinical relevance analysis of HMGN1 expression and patient prognosis.
  • Functional enrichment analysis to identify HMGN1-associated pathways.
  • In vitro cellular experiments to validate HMGN1's role in DNA repair and drug sensitivity.

Main Results:

  • HMGN proteins are frequently dysregulated in LUAD.
  • HMGN1 expression is associated with poor prognosis in LUAD patients.
  • HMGN1 is implicated in homologous recombination repair (HRR).
  • HMGN1 enhances LUAD cell sensitivity to chemotherapy.

Conclusions:

  • HMGN1 is a potential diagnostic marker for differentiating LUAD from healthy controls.
  • HMGN1 serves as a novel prognostic biomarker for LUAD.
  • Targeting HMGN1 may represent a promising therapeutic strategy for LUAD chemotherapy.

More Related Videos

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

967
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
159
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K